In a mouse model of glioma, anti-GITR monoclonal antibody therapy combined with the radiotherapy increased the ratio of CD4+ T cells to Tregs, promoted tumor regression, and significantly improved mouse survival rate (113). Here, TNFRSF18 is linked to neoplasm.